The March 10, 2016, article by Long et al entitled “Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib” (J Clin Oncol 34:871-878, 2016) was published online January 25, 2016, with errors of omission in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.
Dr. Burris’ COIs were given as:
Howard A. Burris III
No relationship to disclose
They should have read as:
Howard A. Burris
Employment: HCA Healthcare/Sarah Cannon
Leadership: HCA Healthcare/Sarah Cannon
Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon
Consulting or Advisory Role: Mersana Therapeutics (Inst), AstraZeneca (Inst), Janssen (Inst), Novartis (Inst), Roche/Genentech (Inst), TG Therapeutics (Inst), MedImmune (Inst), Bristol-Myers Squibb (Inst), Astellas (Inst), Baxter Healthcare (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), Bayer Healthcare (Inst), Merck (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Vertex (Inst), Gilead Sciences (Inst), Sanofi-Aventis (Inst), Chugai (Inst), E.R. Squibb & Sons (Inst), Eisai (Inst), Grifols USA (Inst), Incyte (Inst), Medivation (Inst), Otsuka (Inst), Amgen (Inst), Ipsen (Inst), Prostrakan (Inst), Tolmar (Inst), Genzyme (Inst), Helsinn (Inst), Spectrum Pharmaceuticals (Inst)
Research Funding: Roche/Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), Mersana Therapeutics (Inst), AstraZeneca (Inst), MedImmune (Inst), Macrogenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), AbbVie (Inst), Bayer (Inst), Celldex Therapeutics (Inst), Merck (Inst), Celgene (Inst), Agios Pharmaceuticals (Inst), Jounce Therapeutics (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Immunocore (Inst), Takeda (Inst), Millennium (Inst), BioMed Valley Discoveries (Inst), Pfizer (Inst), TG Therapeutics (Inst), Loxo (Inst), Vertex (Inst), eFFECTOR Therapeutics (Inst), Janssen (Inst), Gilead Sciences (Inst), Valent Technologies (Inst), H3 Biomedicine (Inst), OncoMed (Inst), Regeneron (Inst), Sanofi (Inst), Medivation (Inst), Mirna Therapeutics (Inst), Amgen (Inst), Ventana Medical Systems (Inst), Acerta Pharma (Inst), Exelixis (Inst), Array BioPharma (Inst), StemCentrx (Inst), BIND Therapeutics (Inst)
This has been corrected as of January 7, 2019. The author apologizes for the errors.